We recently published a list of the 10 Best High Short Interest Stocks to Buy Now. In this article, we are going to take a ...

The stock options and RSUs were granted as material inducements to employment in accordance with Nasdaq Listing Rule 5635 (c) ...

BMS could soon face competition in the HCM space as Cytokinetics awaits a marketing application decision from the FDA for ...

Camzyos’ failure in a form of hypertrophic cardiomyopathy dampened its commercial outlook and spurred debate as to whether ...

H.C. Wainwright reiterates Cytokinetics (CYTK) as a top pick after Bristol-Myers (BMY) announced that the Phase 3 ODYSSEY-HCM clinical trial ...

J&J also raised its full-year revenue guidance to include sales of the psychiatric drug Caplyta, which the company got from ...

Bristol Myers Squibb stock skidded late Monday, tugging Cytokinetics lower, after Bristol's drug, Camzyos, failed in a heart disease study.

Heart failure with preserved ejection fraction (HFpEF) is a disease in which the left ventricle (LV) of the heart shows impaired relaxation during cardiac diastole, often accompanied by structural and ...

Needham analyst Serge Belanger maintained a Buy rating on Cytokinetics ( CYTK – Research Report) today and set a price target of $72.00. The company’s shares closed yesterday at $35.99. Filter, ...

California Public Employees Retirement System trimmed its holdings in shares of Cytokinetics, Incorporated (NASDAQ:CYTK – ...

Franklin Resources Inc. boosted its stake in shares of Cytokinetics, Incorporated (NASDAQ:CYTK – Free Report) by 1.7% in the fourth quarter, HoldingsChannel reports. The firm owned 545,813 shares of ...

On Thursday, Cantor Fitzgerald reiterated its Overweight rating on shares of Cytokinetics (NASDAQ:CYTK), with a focus on the company’s heart failure treatment, Afi™. While the stock is currently ...